On Friday, Shares of salesforce.com, inc. (NYSE:CRM), gained 2.88% to $ 75.01.
Salesforce, declared that for the third successive year it has been named the #1 CRM software provider in Gartner Inc.’s latest worldwide CRM market share report, entitled “Market Share Analysis: Customer Relationship Administration Software, Worldwide, 2014.” Based on CRM revenue in 2014, Salesforce achieved greater total revenue, revenue growth and market share growth than any other top 10 CRM vendor. Salesforce also gained the most market share in the worldwide marketing software category based on 2014 total software spend.
salesforce.com, inc. provides enterprise cloud computing solutions, with a focus on customer relationship administration to various businesses and industries worldwide.
Shares of Qihoo 360 Technology Co Ltd(NYSE:QIHU), inclined 0.55% to $ 55.26, during its last trading session.
Qihoo 360, China’s leading Internet security software provider, and Huayuan Group, one of China’s leading real-estate developers, have formed a planned partnership to promote the adoption of smart home and security technologies in China’s real-estate market.
Under the agreement, Qihoo 360 will design and provide intelligent home security products and administration systems for Huayuan’s real-estate developments. These will comprise intelligent surveillance cameras, security routers, location- and health-tracking wearables, electrical appliance safety alarms, intelligent gas and fire alarms, and other devices to assist Huayuan improve and optimize existing security systems and establish new intelligent home security administration systems.
Qihoo 360 Technology Co. Ltd., through its auxiliaries, provides Internet services in the People’s Republic of China. The company operates through Internet Services and Others segments.
At the end of Friday’s trade, Shares of Amgen, Inc. (NASDAQ:AMGN), lost -0.16% to $163.58.
Amgen (AMGN) declared the Company has commenced termination of its participation in the co-development and commercialization of brodalumab with AstraZeneca. Brodalumab, an investigational IL-17 inhibitor, is in development for patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis. The decision was based on events of suicidal ideation and behavior in the brodalumab program, which Amgen believes likely would necessitate restrictive labeling.
“During our preparation process for regulatory submissions, we came to believe that labeling requirements likely would limit the appropriate patient population for brodalumab,” said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen.
Amgen Inc., a biotechnology company, discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses for the treatment of illness in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine.
Finally, Avago Technologies Ltd (NASDAQ:AVGO), ended its last trade with 2.35% gained, and closed at $ 132.64.
Avago Technologies, declared a miniature highly integrated LNA-filter RFIC module, the ALM-2203, targeting Satellite Digital Audio Radio Service (SDARS) car radio systems. The module is designed to enable SDARS signal to coexist with cellular, WiFi, Bluetooth and GPS signals commonly present in today’s automobiles.
Avago Technologies Limited designs, develops, and supplies semiconductor devices with a focus on analog III-V based products. The company operates through four segments: Wireless Communications, Wired Infrastructure, Enterprise Storage, and Industrial & Other segments.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
